Advanced Cell Technology (ACTC.OB) and Roslin Cells Collaboration for hESCs using Blastomere Technology
OTCBB: ACTC has entered into a definitive collaborative agreement with Roslin Cells LTD (“Roslin Cells”) of Scotland. The 2 companies will work together to establish a bank of Good Manufacturing Practice (GMP) grade human embryonic stem cell (hESC) lines using ACT’s patented, proprietary “single-cell blastomere” technique for deriving hESC lines without destroying embryos. Stem cell lines from the resulting bank will be made available for both research and commercial purposes.
The Bottom Line: ACT’s single-cell blastomere technique involves the isolation of a single cell from a 4-to-8 cell embryo, utilizing a one-cell biopsy approach similar to that used in pre-implantation genetic diagnostics (PGD). Under the terms of the agreement, the hESC lines will be created and banked in compliance with the regulations of both the US FDA and the European Medicines Agency (EMA). Roslin Cells will promote access to the hESC lines to both academic and commercial entities, and will establish a straightforward license which should enable 3rd parties to have a predictable path to commercialization, at the time they choose to use the cells for discovery and preclinical research. ACT will continue to control any licenses to commercialization of products for the eye. ACT and Roslin Cells will share proceeds from these licenses, including milestone and royalty payments. No bucks … no bang … sharing the potential …and .. not yet!